BCX4430 freebase

Category	Filovirus
CAS	249503-25-1
Description	BCX4430, a novel synthetic adenosine analogue, inhibits infection of distinct filoviruses in human cells. Interfering with the replication process is a well-established antiviral strategy that has been successfully exploited in developing such life-saving drugs as the nucleoside inhibitors of HIV and acyclovir for herpes simplex complex. BCX4430 may be suitable for administration by intravenous (IV), intramuscular (IM), and oral (PO) routes.

Quotation Now

Product Information

Synonyms	BCX-4430 freebase; BCX 4430 freebase; BCX4430 freebase; Immucillin-A; Immucillin A
IUPAC Name	(2S,3S,4R,5R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol
Molecular Weight	265.27
Molecular Formula	C11H15N5O3
Canonical SMILES	C1=C(C2=C(N1)C(=NC=N2)N)C3C(C(C(N3)CO)O)O
InChI	InChI=1S/C11H15N5O3/c12-11-8-6(14-3-15-11)4(1-13-8)7-10(19)9(18)5(2-17)16-7/h1,3,5,7,9-10,13,16-19H,2H2,(H2,12,14,15)/t5-,7+,9-,10+/m1/s1
InChIKey	AMFDITJFBUXZQN-KUBHLMPHSA-N
Boiling Point	661.2±55.0 °C at 760 mmHg
Flash Point	353.7±31.5 °C
Purity	>98%
Density	1.6±0.1 g/cm3
Solubility	In Vitro: H2O : 1.53 mg/mL(5.77 mM;Need ultrasonic and warming)
Appearance	White to off-white (Solid)
Application	Antiviral Agents
Storage	Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month
Complexity	334
Exact Mass	265.11748936
Index Of Refraction	1.782
In Vitro	Cellular kinases phosphorylate Galidesivir (BCX4430) to a triphosphate that mimics ATP; viral RNA polymerases incorporate the drug's monophosphate nucleotide into the growing RNA chain, causing premature chain termination. Galidesivir effectively inhibits the infection of Vero cells with YFV. The EC50 determined by the neutral red uptake assay is 8.3 μg/ml (24.5 μM).
In Vivo	Galidesivir (BCX4430) is active after intramuscular, intraperitoneal, and oral administration in a variety of experimental infections. In nonclinical studies involving lethal infections with Ebola virus, Marburg virus, Rift Valley fever virus, and Yellow Fever virus, Galidesivir has demonstrated pronounced efficacy. Galidesivir (4 mg/kg; i.p.; twice daily for 7 days) is effectively in a hamster model of yellow fever (YF).
Target	DNA/RNA Synthesis; SARS-CoV; Filovirus
Vapor Pressure	0.0±2.1 mmHg at 25°C
XLogP3-AA	-2.1